The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

They're known to aid in blood sugar control and, now, weight loss — but, according to a sweeping new study, the popular GLP-1 ...

But one Cleveland Clinic expert is imploring executives not to look away. "Preventive measures are often neglected because they don't generate revenue, but they are incredibly important," Leslie Cho, ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

Many Americans have flocked to cheaper, compounded versions of GLP-1 weight loss drugs in lieu of brand-name treatments. That competition is cutting into demand for Novo Nordisk’s prescriptions, a ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition. Previous studies in ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications. Experts break down the findings.

The once- and twice-daily GLP-1 RAs are now well established for their ... It has similar efficacy to other GLP1 agonists, with seemingly lower incidence of nausea. Another important distinction ...

These drugs are known as GLP-1 agonists. GLP-1 is a naturally occurring hormone that works with your brain to control digestion. Drugs like Wegovy agonize the GLP-1 receptors all throughout your body, ...